Merck

Yahoo Finance • 2 months ago

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq... Full story

Yahoo Finance • 3 months ago

Merck & Co., Inc. (MRK): Among the Blue Chip Stocks With Low PE Ratios

We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios.In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other blue chip stocks with low PE ratios. In the current finan... Full story

Yahoo Finance • 3 months ago

Is Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds?

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks among the most promising long-term stocks according to hedge funds. Anot... Full story

Yahoo Finance • 3 months ago

erck & Co. (MRK): Winrevair Approval Drives Cardiovascular Growth

We recently published a list of 7 Most Profitable Cheap Stocks To Invest In. In this article, we are going to take a look at where Merck & Co. (NYSE:MRK) stands against the other most profitable cheap stocks to invest in. Insights on Smal... Full story

Yahoo Finance • 3 months ago

Does Merck (NYSE:MRK) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it might be obvious tha... Full story

Yahoo Finance • 3 months ago

Is Merck & Co Inc. (MRK) the Best Quality Stock to Buy According to Analysts?

We recently compiled a list of 10 Best Quality Stocks to Buy According to Analysts. In this article, we will look at where Merck & Co Inc. (NYSE:MRK) ranks among the best-quality stocks to buy. Income-Focused Investing The stock market h... Full story

Yahoo Finance • 3 months ago

Merck & Co Inc. (MRK): Analysts Are Bullish On This Quality Stock Right Now

We recently compiled a list of the 10 Best Quality Stocks to Buy According to Analysts.In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against the other quality stocks. Income-Focused Investing The... Full story

Yahoo Finance • 3 months ago

Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31

RAHWAY, N.J., October 01, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00... Full story

Yahoo Finance • 3 months ago

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%

Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their trading decisions A total of 25 investors have a majority stake in the company with 45% ownership Ownership research along w... Full story

Yahoo Finance • 3 months ago

7 Best Dialysis and Kidney Disease Stocks to Buy

In this article, we will be taking a look at the 7 best dialysis and kidney disease stocks to buy. Global Kidney Treatment and Dialysis Market: Rapid Growth Amid Rising Prevalence of Kidney Disease The global kidney treatment and dialysi... Full story

Yahoo Finance • 3 months ago

Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts.In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other undervalued wide moat stocks. The... Full story

Yahoo Finance • 3 months ago

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and... Full story

Yahoo Finance • 3 months ago

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treat... Full story

Yahoo Finance • 4 months ago

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally... Full story

Yahoo Finance • 4 months ago

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically significant improvement in OS in this patient population Results from the final analysis of KEYNOTE-811 are being p... Full story

Yahoo Finance • 4 months ago

Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options

KIRKLAND, QC, Sept. 12, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a monotherapy for the... Full story

Yahoo Finance • 4 months ago

Merck to Participate in the Bank of America 2024 Global Healthcare Conference

RAHWAY, N.J., September 11, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fire... Full story

Yahoo Finance • 4 months ago

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half Sunday, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMON... Full story

Yahoo Finance • 4 months ago

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients 12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated... Full story

Yahoo Finance • 4 months ago

Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024

Overall survival (OS) data for KEYTRUDA® (pembrolizumab) in earlier stages of women’s cancers, including high-risk early-stage triple-negative breast cancer (KEYNOTE-522) and high-risk locally advanced cervical cancer (KEYNOTE-A18), select... Full story